Publication, Part of Compendium – Public health indicators

Compendium - Circulatory diseases

Open data

Publication Date:: 22 May 2014
Geographic Coverage:: England, Wales
Geographical Granularity:: Country, Regions, ONS Area Classification, Strategic Health Authorities, Local Authorities, County, Primary Care Organisations, Clinical Commissioning Groups, London Authorities

Summary

To reduce deaths from circulatory diseases.

For information on the definitions of what these indicators include, please see the relevant specification.

As of March 2016, please refer to the data tables published as part of the Quality Outcomes Framework (QOF) for the following indicators:

Prevalence: coronary heart disease: percent, all ages, annual, P (P00958) Exercise testing / specialist referral for patients with newly diagnosed angina: percent, all ages, annual, P, (P00959) Blood pressure in patients with coronary heart disease: percent, all ages, annual, P, (P00960) Cholesterol levels in patients with coronary heart disease: percent, all ages, annual, P, (P00961) Antiplatelet / anti-coagulant therapy for patients with coronary heart disease: percent, all ages, annual, P, (P00962) Beta blocker therapy for patients with coronary heart disease: percent, all ages, annual, P, (P00963) ACE inhibitor therapy for patients with myocardial infarction: percent, all ages, annual, P, (P00964) Prevalence: atrial fibrillation: percent, all ages, annual, P, (P01005) Prevalence: atrial fibrillation confirmed by ECG or specialist: percent, all ages, annual, P, (P01006) Antiplatelet / anti-coagulant therapy for patients with atrial fibrillation: percent, all ages, annual, P, (P01007) Prevalence: heart failure: percent, all ages, annual, P, (P01002) Prevalence: heart failure confirmed by echocardiogram or specialist assessment: percent, all ages, annual, P, (P01003) ACE inhibitor therapy for patients with heart failure due to left ventricular dysfunction: percent, all ages, annual, P, (P01004) ACE inhibitor and beta blocker therapy for patients with heart failure due to left ventricular dysfunction: percent, all ages, annual, P, (P01024) Controlled high blood pressure in patients with hypertension: percent, all ages, annual, P, (P00973) ACE inhibitor / ARB therapy for chronic kidney disease patients with hypertension and proteinuria: percent, 18+ years, annual, P, (P01010) Cardiovascular risk assessment in patients with hypertension: percent, all ages, annual, P, (P01029) Lifestyle advice for patients with hypertension: percent, all ages, annual, P, (P01030) Prevalence: stroke or transient ischaemic attack: percent, all ages, annual, P, (P00966) Referral of patients with stroke for further investigation: percent, all ages, annual, P, (P00967) Blood pressure in patients with stroke or transient ischaemic attack: percent, all ages, annual, P, (P00968) Cholesterol levels in patients with stroke or transient ischaemic attack: percent, all ages, annual, P, (P00969) Antiplatelet / anti-coagulant therapy for patients with stroke or transient ischaemic attack: percent, all ages, annual, P, (P00970) Prevalence: hypertension: percent, all ages, annual, P, (P00972)

As of October 2018, please refer to the Health Survey for England datasets published by NHS Digital for the following indicators:

Systolic blood pressure: standardised mean, 16+ years, annual trend, MFP P00839 Diastolic blood pressure: standardised mean, 16+ years, annual trend, MFP (P00841), High blood pressure : standardised percent, 16+ years, annual trend, MFP (P00843), Treated and controlled high blood pressure: percent and age standardised percent, 16+ years, annual trend, MFP (P00867), Systolic blood pressure: standardised mean, 16+ years, 3-year average trend, MFP (P00838), Diastolic blood pressure: standardised mean, 16+ years, 3-year average trend, MFP (P00840), High blood pressure : standardised percent, 16+ years, 3-year average trend, MFP (P00842), Treated and controlled high blood pressure: percent and age standardised percent, 16+ years, 3-year average trend, MFP (P00866).

The annual publications can be accessed via the link the ‘Resource links’ section.